Loading
A phase 2 trial of Cemiplimab in melanoma and head and neck squamous cell carcinoma, run by Vyriad, Inc., active and no longer recruiting.
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients is a phase 2 interventional study registered as NCT04291105 by Vyriad, Inc., with 87 participants planned, started 2020-04-24 and due to reach its primary completion in 2026-10. Interventions recorded: VV1, Cemiplimab. Conditions listed: Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cemiplimab, Melanoma, Immune checkpoint inhibitors.
Shares Cemiplimab, Melanoma, Immune checkpoint inhibitors.
Shares Cemiplimab, Melanoma, Immune checkpoint inhibitors.
Shares Cemiplimab, Head and neck squamous cell carcinoma, Immune checkpoint inhibitors.
Shares Cemiplimab, Immune checkpoint inhibitors.
Shares Cemiplimab, Immune checkpoint inhibitors.
Shares Cemiplimab, Melanoma, Immune checkpoint inhibitors.
Shares Cemiplimab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/